Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)

Rhea-AI Summary

Aethlon Medical (Nasdaq: AEMD) has secured two significant patents for its Hemopurifier® device: U.S. Patent No. 12,409,260 for Long COVID treatment and European Patent 4136453 for COVID-19-associated coagulopathy (CAC) treatment. The U.S. patent, which expires in 2042, covers treating patients with reduced viral load but persistent Long COVID symptoms and the removal of circulating COVID-19 spike protein. The European patent, expiring in 2041, protects the Hemopurifier's use in treating CAC patients without circulating viral particles.

The U.S. patent received an additional 385-day term adjustment. CEO James Frakes emphasized that while the Hemopurifier® remains in R&D for Long COVID applications, these patents strengthen their intellectual property portfolio in areas with significant unmet medical needs.

Positive

• Secured two strategic patents in US and Europe for Hemopurifier treatment applications
• Long patent protection periods extending to 2041-2042
• Additional 385 days of patent term adjustment granted for US patent
• Expanded intellectual property protection in areas with significant market potential

Negative

• Hemopurifier remains in research and development stage for Long COVID applications
• No immediate revenue impact as treatments are not yet commercialized

SAN DIEGO, Sept. 3, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) announced that U.S. Patent No. 12,409,260 (the "260 Patent") directed to treatment of Long COVID will issue on September 9, 2025, and Unitary European Patent 4136453 (the "453 Patent") directed to the treatment of COVID-19-associated coagulopathy ("CAC") issued July 9, 2025.

The 260 Patent is intended to protect the use of the Hemopurifier^® in the United States to treat patients that have a reduced COVID-19 viral load but exhibit Long COVID symptoms for more than 12 weeks post infection. The 260 Patent additionally protects the treatment of patients experiencing Long COVID symptoms by the removal of circulating COVID-19 spike protein.

The 453 Patent is intended to protect the use of the Hemopurifier^® for the treatment of patients that lack circulating COVID-19 viral particles but exhibit COVID-19-associated CAC.

The 260 Patent was granted an additional 385 days of patent term due to patent term adjustment and will expire in 2042. The 453 Patent will expire in 2041.

"We believe securing these patents expands and strengthens our intellectual property portfolio in areas of significant unmet medical need," said James Frakes, CEO and CFO of Aethlon. "While the Hemopurifier^® remains in the research and development stage relating to Long COVID, these protections position us well as we continue advancing potential future applications. Our goal is to build a strong foundation of innovation that could one day translate into meaningful treatment options for patients."

About the Hemopurifier^®

The Aethlon Hemopurifier^® is an investigational medical device designed to remove enveloped viruses, fragments of viruses, and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viral proteins. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses, fragments of viruses, and extracellular vesicles has been demonstrated in both in vitro studies and in human patients.

The Hemopurifier^® holds a U.S. Food and Drug Breakthrough Device Designation for:

The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier^®, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases, COVID-19 and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; and the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases, the ability of the Company to maintain its current Patents and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-issuance-of-hemopurifier-patents-for-the-treatment-of-long-covid-and-covid-19-associated-coagulopathy-cac-302544201.html

SOURCE Aethlon Medical, Inc.

FAQ

What patents did Aethlon Medical (AEMD) receive for its Hemopurifier device?

Aethlon received U.S. Patent No. 12,409,260 for Long COVID treatment (issuing September 9, 2025) and European Patent 4136453 for COVID-19-associated coagulopathy treatment (issued July 9, 2025).

When do Aethlon Medical's new Hemopurifier patents expire?

The U.S. patent (No. 12,409,260) will expire in 2042, while the European patent (No. 4136453) will expire in 2041.

What conditions will Aethlon Medical's Hemopurifier be used to treat under these patents?

The patents cover the use of Hemopurifier for treating Long COVID symptoms (lasting more than 12 weeks post-infection) and COVID-19-associated coagulopathy (CAC).

Is Aethlon Medical's Hemopurifier currently available for Long COVID treatment?

No, the Hemopurifier is still in the research and development stage for Long COVID applications.

What additional patent term did Aethlon Medical receive for its US patent?

The U.S. patent received an additional 385 days of patent term adjustment.